On this page of StockholderLetter.com we present the latest annual shareholder letter from CEL SCI CORP — ticker symbol CVM. Reading current and past CVM letters to shareholders can bring important insights into the investment thesis.
CEL SCI CORP shareholder letter page 1
CEL SCI CORP shareholder letter page 2
 • Continue to Full 4/9/2025 Report
 • stockholder letter icon 5/8/2015 CVM Stockholder Letter
 • stockholder letter icon 6/8/2016 CVM Stockholder Letter
 • stockholder letter icon 4/27/2017 CVM Stockholder Letter
 • stockholder letter icon 8/8/2018 CVM Stockholder Letter
 • stockholder letter icon 3/26/2019 CVM Stockholder Letter
 • stockholder letter icon 3/4/2020 CVM Stockholder Letter
 • stockholder letter icon 4/29/2022 CVM Stockholder Letter
 • stockholder letter icon 4/10/2023 CVM Stockholder Letter
 • stockholder letter icon 3/7/2024 CVM Stockholder Letter
 • stockholder letter icon More "Biotechnology" Category Stockholder Letters
 • Benford's Law Stocks icon CVM Benford's Law Stock Score = 46


CVM Shareholder/Stockholder Letter Transcript:

CEL SCI CORP shareholder letter page 1CEL SCI CORP shareholder letter page 2

Continue to Full 4/9/2025 Report
 

CVM Stockholder/Shareholder Letter (CEL SCI CORP) | www.StockholderLetter.com
Copyright © 2023 - 2025, All Rights Reserved

Nothing in StockholderLetter.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy.